Centre for the Endothelium, Vascular Biology Program, Centenary Institute, The University of Sydney, Sydney, 2050, Australia.
Liver Injury and Cancer Program, Centenary Institute, The University of Sydney, Sydney, 2050, Australia.
Cancer Lett. 2021 Jan 1;496:1-15. doi: 10.1016/j.canlet.2020.09.026. Epub 2020 Sep 28.
Vascular normalisation, the process that reverses the structural and functional abnormalities seen in tumour-associated vessels, is also accompanied by changes in leucocyte trafficking. Our previous studies have shown the normalisation effects of the agent CD5-2 which acts to stabilise VE-Cadherin leading to increased penetration of CD8 T cells but decreased infiltration of neutrophils (CD11bGr1) into tumour parenchyma. In the present study, we demonstrate that VE-Cadherin stabilisation through CD5-2 treatment of purified endothelial cells (ECs) results in a similar leucocyte-selective regulation of transmigration, suggesting the existence of an endothelial specific intrinsic mechanism. Further, we show by RNA sequencing (RNA-seq)-based transcriptomic analysis, that treatment of ECs with CD5-2 regulates chemokines known to be involved in leucocyte transmigration, including upregulation of CCL2 and CXCL10 that facilitate CD8 T cell transmigration. Both in vitro and in vivo mechanistic studies revealed that the increased CCL2 expression was dependent on expression of VE-Cadherin and downstream activation of the AKT/GSK3β/β-catenin/TCF4 signalling pathway. CD5-2 treatment also contributed to the reorganisation of the cytoskeleton, inducing reorganisation of stress fibres to circumferential actin, which previously has been described as associated with the stabilisation of the endothelial barrier, and amplification of the transcellular migration of CD8 T cells. Thus, we propose that promotion of endothelial junctional integrity during vascular normalisation not only inhibits vascular leak but also resets the endothelial dependent regulation of immune cell infiltration.
血管正常化是指逆转肿瘤相关血管中结构和功能异常的过程,同时伴随着白细胞迁移的变化。我们之前的研究表明,CD5-2 药物具有正常化作用,它可以稳定 VE-钙黏蛋白,从而增加 CD8 T 细胞的穿透性,但减少中性粒细胞(CD11bGr1)浸润肿瘤实质。在本研究中,我们证明通过 CD5-2 处理纯化的内皮细胞(ECs)稳定 VE-钙黏蛋白,导致白细胞迁移的类似选择性调节,这表明存在内皮细胞特异性内在机制。此外,我们通过基于 RNA 测序(RNA-seq)的转录组分析表明,CD5-2 处理 ECs 可调节已知参与白细胞迁移的趋化因子,包括上调 CCL2 和 CXCL10,促进 CD8 T 细胞迁移。体内外机制研究表明,CCL2 表达的增加依赖于 VE-钙黏蛋白的表达和 AKT/GSK3β/β-catenin/TCF4 信号通路的下游激活。CD5-2 处理还导致细胞骨架的重新组织,诱导应激纤维向周向肌动蛋白的重新组织,这以前被描述为与内皮屏障的稳定和 CD8 T 细胞的跨细胞迁移的放大有关。因此,我们提出,在血管正常化过程中促进内皮连接完整性不仅抑制血管渗漏,而且重置内皮对免疫细胞浸润的调节。